Anton E, Costăchescu G, Costăchescu G
Clinica a II-a Obstetrică Ginecologie, Facultatea de Medicină, Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi.
Rev Med Chir Soc Med Nat Iasi. 2001 Jan-Mar;105(1):161-4.
For the increasing of sensibility and specificity in the monitoring of the diagnosis and treatment of breast cancer it is used the simultaneous determination of two tumoral markers: CA 15-3 and CEA. This study try to demonstrate the grade of involvement in diagnostic and screening. We have determinate CA 15-3 and CEA in 73 serum samples. The correlation between the stage of malignancies and CA 15-3 levels was relieved in the second section of this study. The third section follow up the dynamic evolution of CA 15-3 marker in pre- and postoperator (14 days) stages obtaining a decreasing of CA 15-3 level. The obtained results for CEA does not establish any clinical rules in order to compare with the CA 15-3 level and disease stages. The easy-used and non-invasive determination, the early increasing of it's level and it's preservation recommend glycoprotein CA 15-3 like an current clinical instrument.
为了提高乳腺癌诊断和治疗监测的敏感性和特异性，采用了同时测定两种肿瘤标志物：CA 15-3和癌胚抗原（CEA）。本研究试图证明其在诊断和筛查中的参与程度。我们测定了73份血清样本中的CA 15-3和CEA。本研究的第二部分揭示了恶性肿瘤分期与CA 15-3水平之间的相关性。第三部分跟踪了CA 15-3标志物在术前和术后（14天）阶段的动态变化，结果显示CA 15-3水平下降。所获得的癌胚抗原结果未能建立任何临床规律以与CA 15-3水平和疾病分期进行比较。糖蛋白CA 15-3易于使用且为非侵入性检测，其水平早期升高且持续存在，这些特性使其成为一种当前的临床检测手段。
